

July 27, 2026

OSferionBiomaterials Co., Ltd.

Japan Tissue Engineering Co., Ltd.

OSferionBiomaterials and Japan Tissue Engineering Sales Collaboration Agreement to Advance Knee Joint Preservation Through Regenerative Medicine and Osteotomy

OSferionBiomaterials Co., Ltd. (Headquarters: Shibuya-ku, Tokyo; President: Manabu Ishikawa; hereinafter "OSB") and Japan Tissue Engineering Co., Ltd. (Headquarters: Gamagori City, Aichi Prefecture; President: Kazuto Yamada; hereinafter "J-TEC") have entered into a sales collaboration agreement to promote joint-preserving treatment options for knee osteoarthritis by integrating regenerative medicine and osteotomy procedures. Under this agreement, the two companies will begin expanding the availability of their respective products and conducting coordinated promotional activities starting in August 2026.

1. Background

- Knee osteoarthritis is a degenerative joint disease in which abnormal mechanical loading, often caused by varus deformity of the knee, leads to progressive cartilage degeneration, resulting in pain and reduced knee function. An estimated 25.3 million people in Japan are affected by knee osteoarthritis. When conservative treatment fails to adequately relieve pain, surgical options for knee osteoarthritis include procedures such as total knee arthroplasty (TKA) and osteotomy. Among these, osteotomy is widely selected as a joint-preserving procedure that corrects knee alignment to redistribute mechanical load while preserving the patient's native knee joint.
- While osteotomy is an effective procedure for improving the biomechanical environment of the knee, cases involving cartilage defects require a more comprehensive treatment approach that combines mechanical load redistribution with therapies targeting the damaged cartilage itself. This integrated approach is expected to help preserve the patient's native knee joint, improve quality of life, support return to sports, and enable patients to resume an active lifestyle.
- Against this backdrop, OSB, a medical device company specializing in osteotomy, and J-TEC, a regenerative medicine company offering JACC, an autologous cultured cartilage product used in matrix-associated autologous chondrocyte implantation, have entered into a business collaboration agreement to bring joint-preservation treatment combining osteotomy and regenerative medicine into clinical practice.

2. Products Offered by OSB and J-TEC

- OSB is a medical device company engaged in the research, development, manufacturing, and commercialization of surgical solutions for knee osteotomy procedures. Its flagship products include *OSferion*, a bioresorbable ceramic bone graft substitute, and *TriS*, a metallic implant system designed for knee osteotomy procedures.
- J-TEC develops and commercializes JACC, an autologous cultured cartilage product used in matrix-associated autologous chondrocyte implantation. The product is manufactured using chondrocytes harvested from healthy cartilage in the patient's knee and is intended for the treatment of knee cartilage defects and degeneration. In January 2026, it became eligible for reimbursement under Japan's National Health Insurance (NHI) system for the treatment of knee osteoarthritis.


3. Overview of the Business Alliance

- Commercial Collaboration and Mutual Support
OSB will serve as a non-exclusive distributor of JACC, leveraging its established commercial network to promote the product. J-TEC will support OSB in the operational processes involved in providing JACC to healthcare providers while actively introducing OSB's products to healthcare institutions within its network. Through these complementary efforts, the two companies aim to expand the commercial reach of their respective products.
- Educational and Promotional Initiatives
The companies will collaborate on a broad range of educational and promotional initiatives, including participation in educational meetings on knee osteotomy, exhibiting at relevant medical conferences, and co-organizing surgical skills training programs for healthcare professionals to advance awareness and understanding of joint-preservation strategies.

4. Future Outlook

The collaborative initiatives are scheduled to become fully operational in August 2026. Through this partnership, the two companies aim to strengthen their sales networks, expand treatment options for knee osteoarthritis, and advance joint preservation strategies.

OSB is committed to fulfilling its mission, "Return to Active Life – Rediscover the Joy of Free Movement." J-TEC is committed to realizing its vision of "Creating a Future for Regenerative Medicine" and has set a goal of providing JACC treatment to 1,000 patients annually.



TriS Implant System for *OSferion* Bioresorbable Bone Graft Substitute
JACC Autologous Cultured Cartilage
Osteotomies Around the Knee

Comment from Manabu

Ishikawa, Representative Director, President of OSB

"Our vision is to become an essential support for the human body by preserving and restoring physical function. To achieve this vision, we believe that collaboration with J-TEC's advanced regenerative medicine technologies aimed at cartilage regeneration is essential, in addition to osteotomy procedures that correct bone deformities. This shared commitment to advancing joint preservation led us to establish this partnership.

By combining OSB's expertise in correcting bone deformities with J-TEC's expertise in cartilage regeneration, we aim to create new value in joint preservation care. Together, we are committed to helping as many patients as possible rediscover the joy of free movement."

Comment from Kazuto Yamada, Representative Director, President & CEO of J-TEC

"Since JACC became eligible for reimbursement under Japan's National Health Insurance (NHI) system for the treatment of knee osteoarthritis in January 2026, we have received strong interest and high expectations from patients across Japan. To make this treatment available to healthcare providers and patients nationwide in a timely manner, we recognized the importance of partnering with a company that has earned the trust of orthopedic professionals specializing in knee care. Through this partnership with OSB, whose mission is 'Return to Active Life – Rediscover the Joy of Free Movement', we are committed to advancing the broader adoption of joint-preservation treatment for knee osteoarthritis."

About OSferionBiomaterials Co., Ltd.

OSferionBiomaterials Co., Ltd. (OSB) is a medical device company dedicated to its mission, "Return to Active Life – Rediscover the Joy of Free Movement." The company conducts research and development, manufacturing, and commercialization of biomaterials, including artificial bone substitutes, metallic implants, and related surgical support systems. OSB is a wholly owned subsidiary of OrthoActiVolution Holdings Co., Ltd. OSB is a market leader in surgical solutions for osteotomy around the knee. The company develops a broad portfolio of implants and surgical solutions designed to accommodate a wide range of patient anatomies. In addition to product innovation, OSB works closely with healthcare professionals to plan and deliver educational programs, while actively supporting regional study groups, seminars, and other initiatives that promote safe and effective surgical practice.

About Japan Tissue Engineering Co., Ltd.

Japan Tissue Engineering Co., Ltd. (J-TEC) is a regenerative medicine company dedicated to its vision of "Making Regenerative Medicine a Standard Treatment Option." Since March 2021, the company has been a member of the Teijin Group. As a pioneer in regenerative medicine in Japan, J-TEC has commercialized five regenerative medicine products, including *JACE*, the first regenerative medicine product to receive regulatory approval in Japan in October 2007. Its product portfolio includes products for the treatment of epidermal, knee cartilage, and corneal epithelial disorders, contributing to the advancement of regenerative medicine and improved patient care.

-End-

[Contact for Inquiries about OSB Products]

OSferionBiomaterials Co., Ltd., Business Planning Department

Email: OTB-SEC-BPRM@biomaterial.co.jp

Tel: 03-5738-3410

[Contact for Media and Inquiries about J-TEC Products]

Japan Tissue Engineering Co., Ltd., Corporate Management Department

Email: jtec-info@jpte.co.jp